Last reviewed 2026-05-14 · How we verify

Suplexedil (FENOXEDIL)

Phase 2 active Small molecule

Suplexedil (generic name: FENOXEDIL) is a fenoxedil drug. It is currently in Phase 2 development.

Fenoxedil works by inhibiting the enzyme that breaks down certain herbicides, allowing them to be more effective.

Suplexedil, also known as Fenoxedil, is a small molecule drug of the fenoxedil class. Its original development is attributed to an unknown entity, and its current ownership is also unclear. The target and approved indications of Suplexedil are unknown, and its commercial status, including patent status and generic availability, is also unclear. Further research is needed to determine the key safety considerations and pharmacokinetic properties of Suplexedil. As a result, its clinical use and potential benefits remain uncertain.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENOXEDIL
Drug class	fenoxedil
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body is like a garden, and herbicides are like weed killers. Fenoxedil helps the weed killers work better by blocking the 'gardener' that breaks them down. This allows the weed killers to stay in the garden longer and kill more weeds.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Suplexedil CI brief — competitive landscape report
Suplexedil updates RSS · CI watch RSS

Frequently asked questions about Suplexedil

What is Suplexedil?

Suplexedil (FENOXEDIL) is a fenoxedil drug.

How does Suplexedil work?

Fenoxedil works by inhibiting the enzyme that breaks down certain herbicides, allowing them to be more effective.

What is the generic name of Suplexedil?

FENOXEDIL is the generic (nonproprietary) name of Suplexedil.

What drug class is Suplexedil in?

Suplexedil belongs to the fenoxedil class. See all fenoxedil drugs at /class/fenoxedil.

What development phase is Suplexedil in?

Suplexedil is in Phase 2.

Drug class: All fenoxedil drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing